Sofinnova Partners, a France-based European life sciences venture capital firm, has announced the final close of Sofinnova MD Start IV at €82m (US$93m). The fund, which was oversubscribed, will help expand Sofinnova’s medtech company-creation strategy across Europe and the US with greater capacity to launch new ventures and support them through key stages of development.
“Sofinnova MD Start is one of the few strategies in Europe focused on creating medtech companies from the ground up,” said Antoine Papiernik, chairman and managing partner of Sofinnova. “What makes the model distinctive is the active role our team plays in building and supporting every company from day one. This latest fund will allow us to scale that approach and remain a key part of Sofinnova’s platform across the life sciences value chain.”
Sofinnova MD Start IV will launch six to eight new medtech companies over the next five years, supporting ventures from inception through key clinical and operational milestones, providing founders with both capital and hands-on support.
“With Sofinnova MD Start IV, we look forward to continuing to work closely with engineers, clinicians, and scientists to advance their transformative medical technologies from the lab to the clinic,” said Anne Osdoit, partner at Sofinnova.
The previous fund, a €63m fund, invested across six companies that have collectively raised more than €140m in follow-on financing.
The investment strategy is led by partners Osdoit, Cecile Dupont, and Mano Iyer, together with principal Marion Gasperment, analyst Jérémie Wisniewski and venture partners Gérard Hascoët, and Josh Makower.
